23 results
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
20 Dec 22
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
4:19pm
criteria: Treat single migraine of attack of moderate or severe pain intensity Key secondary endpoints 18-65 years of age Co-primary endpoints: % Pain-free … Pain freedom ✓ 3h* -48h* all trials in NDA [n=13] that MIGRANAL controlled No monotherapy, attenuatedattacks in both pain intensity trial; same
8-K
EX-99.1
STSA
Satsuma Pharmaceuticals Inc
30 Nov 22
Other Events
4:00pm
by attenuated attacks in both pain intensity Total Migraine Freedom✓ 3h* - 48h* reference and duration of symptoms, but did not abort attacks MBS … that no effectiveness not Intensity, evaluated at both 2h and 4h post- other DHE product has shown in a placebo-controlled trial, supported by any treatment
8-K
EX-99.2
STSA
Satsuma Pharmaceuticals Inc
14 Nov 22
Satsuma Pharmaceuticals Announces Topline Results from SUMMIT Phase
4:04pm
migraine of attack of moderate or severe pain intensity Co-primary endpoints: % free from headache pain at 2h post-treatment % free from most bothersome
8-K
EX-99.2
9eue8q2v
1 Mar 21
Satsuma Pharmaceuticals Announces Updated STS101 Development Plan
12:00am
10-K
ph04qwhg2z 5m2qr34x
10 Mar 20
Annual report
4:20pm
10-Q
4r7b2m
12 Nov 19
Quarterly report
4:31pm
424B4
corg27z yg
13 Sep 19
Prospectus supplement with pricing info
5:08pm
S-1/A
ljtshlmgpjp6 w2vm
3 Sep 19
IPO registration (amended)
6:12am